Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 2
1992 1
1993 1
1994 1
1997 2
2001 2
2002 3
2003 1
2005 1
2006 3
2007 3
2009 1
2011 3
2012 2
2019 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

24 results
Results by year
Filters applied: . Clear all
Page 1
Comparison between two classes of selective EP(3) antagonists and their biological activities.
Belley M, Chan CC, Gareau Y, Gallant M, Juteau H, Houde K, Lachance N, Labelle M, Sawyer N, Tremblay N, Lamontagne S, Carrière MC, Denis D, Greig GM, Slipetz D, Gordon R, Chauret N, Li C, Zamboni RJ, Metters KM. Belley M, et al. Among authors: lachance n. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5639-42. doi: 10.1016/j.bmcl.2006.08.025. Epub 2006 Aug 22. Bioorg Med Chem Lett. 2006. PMID: 16931013
Discovery of potent and selective DP1 receptor antagonists in the azaindole series.
Leblanc Y, Roy P, Dufresne C, Lachance N, Wang Z, O'Neill G, Greig G, Denis D, Mathieu MC, Slipetz D, Sawyer N, Tsou N. Leblanc Y, et al. Among authors: lachance n. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2125-8. doi: 10.1016/j.bmcl.2009.03.010. Epub 2009 Mar 9. Bioorg Med Chem Lett. 2009. PMID: 19307115
Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524).
Sturino CF, O'Neill G, Lachance N, Boyd M, Berthelette C, Labelle M, Li L, Roy B, Scheigetz J, Tsou N, Aubin Y, Bateman KP, Chauret N, Day SH, Lévesque JF, Seto C, Silva JH, Trimble LA, Carriere MC, Denis D, Greig G, Kargman S, Lamontagne S, Mathieu MC, Sawyer N, Slipetz D, Abraham WM, Jones T, McAuliffe M, Piechuta H, Nicoll-Griffith DA, Wang Z, Zamboni R, Young RN, Metters KM. Sturino CF, et al. Among authors: lachance n. J Med Chem. 2007 Feb 22;50(4):794-806. doi: 10.1021/jm0603668. J Med Chem. 2007. PMID: 17300164
Assessing the emetic potential of PDE4 inhibitors in rats.
Robichaud A, Savoie C, Stamatiou PB, Lachance N, Jolicoeur P, Rasori R, Chan CC. Robichaud A, et al. Among authors: lachance n. Br J Pharmacol. 2002 Jan;135(1):113-8. doi: 10.1038/sj.bjp.0704457. Br J Pharmacol. 2002. PMID: 11786486 Free PMC article.
Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia.
Oballa RM, Belair L, Black WC, Bleasby K, Chan CC, Desroches C, Du X, Gordon R, Guay J, Guiral S, Hafey MJ, Hamelin E, Huang Z, Kennedy B, Lachance N, Landry F, Li CS, Mancini J, Normandin D, Pocai A, Powell DA, Ramtohul YK, Skorey K, Sørensen D, Sturkenboom W, Styhler A, Waddleton DM, Wang H, Wong S, Xu L, Zhang L. Oballa RM, et al. Among authors: lachance n. J Med Chem. 2011 Jul 28;54(14):5082-96. doi: 10.1021/jm200319u. Epub 2011 Jun 28. J Med Chem. 2011. PMID: 21661758
24 results